These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24080590)

  • 21. Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Hata M; Tsujikawa A; Miyake M; Yamashiro K; Ooto S; Oishi A; Nakanishi H; Takahashi A; Yoshimura N
    Graefes Arch Clin Exp Ophthalmol; 2015 Feb; 253(2):221-7. PubMed ID: 24961698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CFH Y402H polymorphism and response to intravitreal ranibizumab in Brazilian patients with neovascular age-related macular degeneration.
    Veloso CE; Almeida LN; Nehemy MB
    Rev Col Bras Cir; 2014; 41(6):386-92. PubMed ID: 25742403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD.
    Kloeckener-Gruissem B; Barthelmes D; Labs S; Schindler C; Kurz-Levin M; Michels S; Fleischhauer J; Berger W; Sutter F; Menghini M
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(7):4694-702. PubMed ID: 21282580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study.
    Lotery AJ; Gibson J; Cree AJ; Downes SM; Harding SP; Rogers CA; Reeves BC; Ennis S; Chakravarthy U;
    Ophthalmology; 2013 Dec; 120(12):2637-2643. PubMed ID: 24070809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab.
    Dikmetas O; Kadayıfcılar S; Eldem B
    Mol Vis; 2013; 19():2571-8. PubMed ID: 24367156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Makalic E; Schmidt DF; Sandhu SS; Baird PN; Guymer RH
    Ophthalmology; 2013 Jan; 120(1):115-21. PubMed ID: 23149126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenotype and genotype characteristics of age-related macular degeneration in a Japanese population.
    Mori K; Horie-Inoue K; Gehlbach PL; Takita H; Kabasawa S; Kawasaki I; Ohkubo T; Kurihara S; Iizuka H; Miyashita Y; Katayama S; Awata T; Yoneya S; Inoue S
    Ophthalmology; 2010 May; 117(5):928-38. PubMed ID: 20132989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined effects of genetic and non-genetic risk factors affect response to ranibizumab in exudative age-related macular degeneration.
    Piermarocchi S; Miotto S; Colavito D; Leon A; Segato T
    Acta Ophthalmol; 2015 Sep; 93(6):e451-7. PubMed ID: 25402348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of the CFH Y402H Polymorphism with the 1-Year Response of Exudative AMD to Intravitreal Anti-VEGF Treatment in the Brazilian Population.
    Medina FMC; Motta AALD; Takahashi WY; Carricondo PC; Motta MMDS; Melo MB; Vasconcellos JPC
    Ophthalmic Res; 2019; 61(3):168-173. PubMed ID: 28641277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of Genetic Polymorphisms on the Short-Term Response to Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration.
    García-Quintanilla L; Almuiña-Varela P; Maroñas O; Gil-Rodriguez A; Rodríguez-Cid MJ; Gil-Martinez M; Abraldes MJ; Gómez-Ulla de Irazazabal F; González-Barcia M; Mondelo-Garcia C; Cruz R; Estany-Gestal A; Fernández-Rodríguez M; Fernández-Ferreiro A
    Invest Ophthalmol Vis Sci; 2023 Oct; 64(13):34. PubMed ID: 37862026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment: A Retrospective Cohort Study.
    Kuroda Y; Yamashiro K; Miyake M; Yoshikawa M; Nakanishi H; Oishi A; Tamura H; Ooto S; Tsujikawa A; Yoshimura N
    Ophthalmology; 2015 Nov; 122(11):2303-10. PubMed ID: 26271842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.
    Hagstrom SA; Ying GS; Maguire MG; Martin DF; ; Gibson J; Lotery A; Chakravarthy U;
    Ophthalmology; 2015 Aug; 122(8):1563-8. PubMed ID: 26028346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting non-response to ranibizumab in patients with neovascular age-related macular degeneration.
    van Asten F; Rovers MM; Lechanteur YT; Smailhodzic D; Muether PS; Chen J; den Hollander AI; Fauser S; Hoyng CB; van der Wilt GJ; Klevering BJ
    Ophthalmic Epidemiol; 2014 Dec; 21(6):347-55. PubMed ID: 25157998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of CFH, LOC387715, and HTRA1 polymorphisms with exudative age-related macular degeneration in a northern Chinese population.
    Xu Y; Guan N; Xu J; Yang X; Ma K; Zhou H; Zhang F; Snellingen T; Jiao Y; Liu X; Wang N; Liu N
    Mol Vis; 2008 Jul; 14():1373-81. PubMed ID: 18682812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials.
    Grunwald JE; Pistilli M; Ying GS; Maguire MG; Daniel E; Martin DF;
    Ophthalmology; 2015 Apr; 122(4):809-16. PubMed ID: 25542520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Association between Y402H, E318D and R102G polymorphisms of complement proteins genes and the response to intravitreal anti-VEGF treatment in patients with neovascular age-related macular degeneration].
    Kubicka-Trząska A; Karska-Basta I; Kobylarz J; Dziedzina S; Sanak M; Romanowska-Dixon B
    Klin Oczna; 2016; 118(2):114-21. PubMed ID: 29912491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population.
    Kang HK; Yoon MH; Lee DH; Chin HS
    Korean J Ophthalmol; 2012 Dec; 26(6):414-22. PubMed ID: 23204795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic variants in three genes and smoking show strong associations with susceptibility to exudative age-related macular degeneration in a Chinese population.
    Chu J; Zhou CC; Lu N; Zhang X; Dong FT
    Chin Med J (Engl); 2008 Dec; 121(24):2525-33. PubMed ID: 19187590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration.
    Nischler C; Oberkofler H; Ortner C; Paikl D; Riha W; Lang N; Patsch W; Egger SF
    Acta Ophthalmol; 2011 Jun; 89(4):e344-9. PubMed ID: 21232084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration.
    Kent JS; Iordanous Y; Mao A; Powell AM; Kent SS; Sheidow TG
    Can J Ophthalmol; 2012 Apr; 47(2):159-64. PubMed ID: 22560422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.